How Scotland Plans To Improve Access To Drugs For Very Rare Diseases
Executive Summary
Scotland is to change the way it appraises new drugs for very rare diseases for use on the National Health Service, with a new “conditional yes” option for the Scottish Medicines Consortium that will require further evidence-gathering and subsequent reassessment, and a new appraisal procedure for “true ultra-orphan drugs” for very rare conditions where a cost-benefit assessment may not be appropriate. There will also be provision for earlier engagement on orphan drug pricing with the pharmaceutical industry and for more patient involvement in the SMC’s processes.
You may also be interested in...
Scottish HTA Body Prepares For ‘Conditional Yes’ On Certain New Drugs
Scotland’s HTA body, the Scottish Medicines Consortium, is about to embark on a new system allowing it to give a “conditional yes” to medicines for which data may be limited at the time of marketing authorization. At the same time, changes are being implemented to the system for allowing patient access to drugs that have not been recommended by the SMC.
Three ways Scottish HTA reforms could benefit pharma
Scotland recently announced significant changes to the way it assesses medicines for availability on the NHS, which could benefit pharma companies looking for access in this small but influential market. Among the reforms, Scotland's health technology appraisal body the Scottish Medicines Consortium (SMC) plans to give patients and clinicians a stronger voice in assessments, and to give companies the opportunity to submit patient access schemes to make their drugs more affordable.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.